6-(2-硝基-4-叠氮基苯基氨基)己酸 | 58775-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-(2-硝基-4-叠氮基苯基氨基)己酸
• 英文名称: 6-(2-Nitro-4-azidophenylamino)caproate
• 英文别名: 6-(4-azido-2-nitroanilino)hexanoic acid
• CAS: 58775-38-5
• 化学式: C₁₂H₁₅N₅O₄
• 分子量: 293.282
• InChiKey: LOFJQDXNFNAVOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-(2-硝基-4-叠氮基苯基氨基)己酸 在 4-二甲氨基吡啶 、 水 、 对甲苯磺酸 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 19-methyl[6''-(4-azido-2-nitrophenyl)amino]hexanoyl,25-hydroxy 5E-vitamin D3-3β-(2'-bromoacetate)
  参考文献：
  名称：

  Development of an affinity-driven cross-linker: isolation of a vitamin D receptor associated factor

  摘要：

  A vitamin D analogue containing an affinity and a photoaffinity probe (affinity-driven cross-linker, Double Label) was synthesized. An unknown factor, associated with vitamin D receptor (VDR), was isolated from rat liver nuclear extract using a GST-VDR-ligand-binding domain fusion protein (GST-VDR-LBD), affinity labeled with Double Label, and protein-protein crosslinking by photolysis. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00009-3
• 作为产物：
  描述：

  4-叠氮基-1-氟-2-硝基苯 、 6-氨基己酸 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成 6-(2-硝基-4-叠氮基苯基氨基)己酸
  参考文献：
  名称：

  Development of an affinity-driven cross-linker: isolation of a vitamin D receptor associated factor

  摘要：

  A vitamin D analogue containing an affinity and a photoaffinity probe (affinity-driven cross-linker, Double Label) was synthesized. An unknown factor, associated with vitamin D receptor (VDR), was isolated from rat liver nuclear extract using a GST-VDR-ligand-binding domain fusion protein (GST-VDR-LBD), affinity labeled with Double Label, and protein-protein crosslinking by photolysis. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00009-3

文献信息

• A precursor for biological probes, uses thereof and methods of its synthesis
  申请人：Bio-Med Reagents Limited

  公开号：EP1429144A1

  公开（公告）日：2004-06-16

  There is provided a compound comprising a label moiety attached to a linker, the linker having an attachment site adapted for attachment to a ligand, the compound further comprising a photo-reactive group attached to the linker. Such a compound can advantageously be used as a pre-probe for the preparation of bioprobes. Methods of making such pre-probes and bioprobes are also provided.

  本发明提供了一种化合物，该化合物包括连接到连接体上的标记分子，连接体具有适于连接配体的连接位点，该化合物还包括连接到连接体上的光反应基团。这种化合物可用作制备生物探针的前探针。此外，还提供了制造这种前探针和生物探针的方法。
• Site-directed coupling of proteins
  申请人：Vectron Therapeutics AG

  公开号：EP1557429A1

  公开（公告）日：2005-07-27

  The present invention relates to a method of modifying a polypeptide, which yields a modified polypeptide, suitable for site-specific coupling, for example, as a targeting ligand, as well as modified human EGF and fragments thereof, suitable for site-specific coupling.

  本发明涉及一种修饰多肽的方法，该方法可获得适合于位点特异性偶联的修饰多肽，例如作为靶向配体，以及适合于位点特异性偶联的修饰人EGF及其片段。
• Complement factor H-derived short consensus repeat-antibody constructs
  申请人：Medizinische Universität Innsbruck

  公开号：EP2208737A1

  公开（公告）日：2010-07-21

  The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described.

  本发明涉及一种补体激活构建物，该构建物由补体因子 H 衍生的短共识重复序列（fH-derived SCR）和特异性识别病原体的结合分子组成。更具体地说，fH-衍生SCR选自SCR7、SCR9、SCR13、SCR18-20和人工SCR（aSCR）组成的组。此外，还描述了一种体内方法，用于筛选基于补体的治疗方法，以预防、治疗或改善病原体感染或与病原体感染相关的病理状况。
• Devices including protein matrix materials and methods of making and using thereof
  申请人：Gel-Del Technologies, Inc.

  公开号：EP2371352A9

  公开（公告）日：2012-05-16

  A device comprising biocompatible protein matrix materials and their method of preparation and use, wherein the device is a protein matrix diagnostic array, a protein matrix coated implantable medical device or an electromatrix device. The biocompatible protein matrix materials comprise one or more biocompatible proteins and one or more biocompatible solvents. The protein matrix diagnostic array can be used in a method of determining pharmacologically active agent to protein interaction.

  一种包含生物相容性蛋白质基质材料的装置及其制备和使用方法，其中该装置是蛋白质基质诊断阵列、蛋白质基质涂层植入式医疗装置或电基质装置。生物相容性蛋白质基质材料包括一种或多种生物相容性蛋白质和一种或多种生物相容性溶剂。蛋白质基质诊断阵列可用于确定药理活性剂与蛋白质相互作用的方法。
• Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
  申请人：Masters David B.

  公开号：US10016534B2

  公开（公告）日：2018-07-10

  The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.

  本发明涉及心血管应用和其他医疗应用中使用的蛋白质生物凝胶和生物材料血管移植系统、血管移植系统中使用的组件以及制造和使用此类系统的方法。更具体地说，本发明涉及在各种医疗应用中使用的蛋白质生物凝胶和生物材料血管移植系统和/或在此类血管移植系统中使用的装置，包括但不限于作为控制释放药理活性剂的给药装置的血管移植、管状移植、血管移植、蛋白质生物材料缝合线和生物粘合剂、蛋白质生物材料粘合剂和胶水，以及在本发明血管移植系统中使用的其它生物相容性生物凝胶或生物材料装置。